CI 988

Key Product Details

Product Description

CI 988 is a potent and selective CCK₂ (CCK-B) receptor antagonist that displays ~ 1600-fold selectivity over CCK₁ receptors (IC₅₀ values are 1.7 and 2717 nM for CCK₂ and CCK₁ respectively). Has negligible affinity at a range of other binding sites (IC₅₀ > 10 μM). Exhibits anxiolytic activity following oral administration.

Product Specifications for CI 988

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

Solubility

Preparing Stock Solutions for CI 988

The following data is based on the product molecular weight 614.73.

Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which all affect the solvent volumes required to prepare stock solutions.

Select a batch to recalculate based on the batch molecular weight:

1 Recalculate

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.63 mL	8.13 mL	16.27 mL
5 mM	0.33 mL	1.63 mL	3.25 mL
10 mM	0.16 mL	0.81 mL	1.63 mL
50 mM	0.03 mL	0.16 mL	0.33 mL

Calculators

Background References

References are publications that support the biological activity of the product. See our Citations tab to view 15 publications citing the usage of this product.

• Andre Involvement of cholecystokininergic systems in anxiety-induced hyperalgesia in male rats: behavioral and biochemical studies. J.Neurosci. 2005 PMID: 16135746
• Hughes Development of a class of selective cholecystokinin type B receptor antagonists having potent anxiolytic activity. Proc.Natl.Acad.Sci.USA
• Moody CI-988 inhibits growth of small cell lung cancer cells. J.Pharmacol.Exp.Ther. 2001 PMID: 11714907

Product Documents for CI 988